A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

Chatterjee M, Neema S, Rajput GR

Indian journal of dermatology, venereology and leprology1 Jan 2021Cited by 2 (Europe PMC)

PMID34379946DOI10.25259/ijdvl_976_18PepBankPUB-34379946

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Nonapeptide-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nonapeptide-1.

01HumanNot a test of Nonapeptide-1 aloneRandomized controlled trialEfficacy outcome
In melasma maintenance, the nonapeptide‑1 combination did not significantly improve melasma severity score versus sunscreen alone.
In plain wordsIn melasma maintenance, the nonapeptide‑1 combination did not significantly improve severity score versus sunscreen alone.
Peptide
Nonapeptide-1
Outcome
No significant changeMelasma severity score
Study
n = 46
Comparator
Sunscreen alone
Outcome group
Skin and hair · Skin and wound
Source sentences
Summary
Case group in the study showed improvement in the melasma severity score and mean melanin index as measured by mexameter but it did not attain statistical significance as compared to the control group.
4 context sentences(design, population, supporting numbers)
Summary · context
(i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,
Summary · context
It was a prospective double-blinded parallel-group randomized controlled pilot study.
Summary · context
A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups.
Summary · context
Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen.
In this study, Nonapeptide-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nonapeptide-1.
Report a problemFND-3437994601
02HumanNot a test of Nonapeptide-1 aloneRandomized controlled trialEfficacy outcome
In melasma maintenance, the nonapeptide‑1 combination did not significantly improve mean melanin index versus sunscreen alone.
In plain wordsIn melasma maintenance, the nonapeptide‑1 combination did not significantly improve mean melanin index versus sunscreen alone.
Peptide
Nonapeptide-1
Outcome
No significant changeMean melanin index
Study
n = 46
Comparator
Sunscreen alone
Outcome group
Skin and hair · Skin and wound
Source sentences
Summary
Case group in the study showed improvement in the melasma severity score and mean melanin index as measured by mexameter but it did not attain statistical significance as compared to the control group.
4 context sentences(design, population, supporting numbers)
Summary · context
(i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,
Summary · context
It was a prospective double-blinded parallel-group randomized controlled pilot study.
Summary · context
A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups.
Summary · context
Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen.
In this study, Nonapeptide-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nonapeptide-1.
Report a problemFND-3437994602
03HumanNot a test of Nonapeptide-1 aloneRandomized controlled trialEfficacy outcome
In melasma maintenance, melasma area and severity index decreased with the nonapeptide‑1 combination but increased with sunscreen alone from baseline.
In plain wordsIn melasma maintenance, melasma area and severity index decreased with the nonapeptide‑1 combination but increased with sunscreen alone.
Peptide
Nonapeptide-1
Outcome
DecreaseMelasma area and severity index score
Study
n = 46
Comparator
Sunscreen alone
Outcome group
Skin and hair · Skin and wound
Source sentences
Summary
The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
(i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,
Summary · context
It was a prospective double-blinded parallel-group randomized controlled pilot study.
Summary · context
A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups.
Summary · context
Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen.
In this study, Nonapeptide-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nonapeptide-1.
Report a problemFND-3437994603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.